Chris Viehbacher

illustration of two people putting puzzle pieces together merger and acquisition concept
Biotech

Biogen inks $1.15B HI-Bio buyout to expand in immunology

HI-Bio is preparing to advance an anti-CD38 monoclonal antibody into phase 3 in multiple rare immune-mediated indications.
Nick Paul Taylor May 22, 2024 8:24am
brain alzheimers dementia neuroscience gears thought think

To be better at neuroscience, Biogen will invest elsewhere

Apr 24, 2024 10:37am
Graphic of someone identifying a candidate out of a crowd using a magnifying class

New Biogen research chief aims to add biotech hustle to pharma

Oct 10, 2023 10:50am
Alice in Wonderland tea party cup key clock watch

Biogen's tight-lipped zuranolone remarks disquiet Sage investors

Jul 26, 2023 10:45am